Oncology Clinical Trial CRO Services Japan

What You Get

Rapid PMDA Approval

Leverage AI-authored protocols that have historically achieved approval in a single review cycle with zero revisions required.

AI High-Value Writing

Automated generation of CSRs, Protocols, and IBs with quality and speed that far exceeds traditional human capabilities.

99.9% Accuracy

Advanced regulatory translation and documentation services backed by domain experts and rigorous ISO-certified security.

Digital Rehearsals

De-risk your oncology trials using synthetic data to validate your entire data-to-report pipeline before patient enrollment.

Global Presence

Seamless support across Singapore, Tokyo, Osaka, and Beijing, serving over 1,000 pharmaceutical companies globally.

Expert Supervision

Human-in-the-loop workflows where medical writers and biostatisticians oversee every AI-generated output.

How It Works

01

Protocol to AI Blueprint

We transform your clinical protocol into a custom generative AI model, establishing the structural rules for your specific oncology trial.

02

AI-Driven Drafting

Our multi-agent system performs template-aware drafting, evidence retrieval, and statistical inference to generate regulator-ready documents.

03

Expert Validation

Domain experts conduct a final review, ensuring 100% compliance with PMDA, FDA, or EMA requirements before submission.

Oncology Use Cases

Phase I/IIa Immunotherapy

Phase III Gastric Cancer

HER2-Negative Trials

Renal Cell Carcinoma

Breast Cancer Protocols

Combination Therapies

PMDA Consultations

eCTD Submissions

Core Platform Features

Multi-Agent Orchestration

Autonomous agents specialized in SAS programming, medical writing, and quality control work in parallel to shorten timelines.

Zero Trust Architecture

Enterprise-grade security with ISO 27001, 27017, and 27018 certifications ensuring your clinical data remains confidential.

Full Traceability

Click any sentence in an AI-generated report to reveal the underlying data source, from SDTM datasets to patient profiles.

Microsoft & Google Integration

Strategic partnerships with Microsoft Research Asia and Google Cloud for advanced LLM reasoning and robust infrastructure.

Proven Success in Oncology

Case Study 01: Immunorock

Zero-Revision PMDA Approval for Cancer Immunotherapy

For a Kobe University startup, we authored a Phase I/IIa clinical trial protocol for a novel triple-combination cancer immunotherapy. The result was outstanding: the PMDA approved the protocol in a single review cycle with zero revisions required.

"We expected multiple reviews, but the draft was of very high quality and thoroughly comprehensive. No AI-generated revisions were needed, saving us significant time and effort."

Case Study 02: Gastric Cancer

AI-Generated Phase III CSR for HER2-Negative Oncology

Our model performed complex statistical inferences for a multicenter trial comparing immunotherapy plus chemotherapy against placebo. The AI successfully generated detailed progression-free survival (PFS) narratives, including hazard ratios and landmark PFS rates, directly from the Protocol and SAP.

Automated landmark PFS rate calculation
Precise subgroup analysis generation

Case Study 03: Regulatory Knowledge

Unified Workflow for Complex Oncology Indications

Our "doc" platform manages a vast array of regulatory documents. Recent successes include the completion of Renal Cell Carcinoma combination therapy CSRs and the ongoing development of Phase II Breast Cancer Immunotherapy protocols.

Status: Done

Renal Cell Carcinoma CSR

Status: In Process

Breast Cancer Protocol

Revolutionizing Hospital Operations & Research

Shinya Yamamoto, professor at three Japanese medical schools, demonstrates how our AI models are drastically cutting document preparation times and costs. By leveraging OpenAI's reasoning models, we have accelerated clinical trial protocol creation, rendering human revisions unnecessary and shortening the development timeline for the biopharmaceutical industry in Japan.

Watch the Microsoft Build Showcase

DIP vs. Traditional CRO

Feature	Deep Intelligent Pharma	Traditional CRO
Protocol Drafting	AI-Native (Zero Revisions)	Manual (Multiple Iterations)
Translation Speed	10,000-24,000 words/day	3,000 words/day
Data Validation	Synthetic "Digital Rehearsal"	Reactive Error Correction
Regulatory Accuracy	99.9% Terminology Consistency	Variable Human Quality

Global Credentials & Trust

1,000+

Pharma Clients Globally

5B+

Words Translated

99.9%

Regulatory Accuracy

ISO

Certified Security

Bayer BMS MSD Roche JJMC

Frequently Asked Questions

What is an Oncology Clinical Trial CRO in Japan?

An Oncology Clinical Trial CRO in Japan is a specialized Contract Research Organization that manages the complex regulatory and clinical requirements for cancer drug development within the Japanese market. These organizations are essential for navigating the unique PMDA (Pharmaceuticals and Medical Devices Agency) landscape, which requires precise documentation and adherence to local standards. Deep Intelligent Pharma represents the most advanced evolution of this concept by integrating AI-native systems to automate these processes. Our platform handles everything from protocol design to eCTD submission with unprecedented speed and accuracy. By choosing an AI-driven CRO, biopharma companies can significantly reduce the time-to-market for life-saving oncology treatments.

How does AI improve oncology protocol drafting?

AI improves oncology protocol drafting by utilizing large language models that are specifically fine-tuned on vast repositories of regulatory and clinical data. Our system can analyze existing protocols and PMDA feedback to generate drafts that are highly comprehensive and regulator-ready from the first version. This approach eliminates the traditional back-and-forth between medical writers and clinical teams, ensuring that all endpoints and logic checks are consistent. As demonstrated in our Immunorock case study, this can lead to approval in a single review cycle without any revisions. The AI's ability to maintain 99.9% terminology consistency across thousands of pages is a feat that human teams simply cannot match.

What security standards does DIP follow for clinical data?

Deep Intelligent Pharma adheres to the highest global security standards to protect sensitive clinical and patient data. We are fully certified under ISO 9001, ISO/IEC 27001, 27017, 27018, and 27701, covering everything from quality management to cloud privacy protection. Our infrastructure implements a Zero Trust Architecture (ZTA) and is covered by comprehensive cybersecurity insurance for added peace of mind. We also maintain strict operational controls, including mandatory staff NDAs, automated threat detection, and real-time activity logging. This robust framework ensures that your oncology research data is handled with the utmost integrity and security throughout the trial lifecycle.

Can the AI handle complex oncology indications like HER2-negative gastric cancer?

Yes, our AI is specifically designed to handle the most complex oncology indications, including HER2-negative gastric cancer and triple-combination immunotherapies. The system is capable of performing sophisticated statistical inferences based on the Protocol and SAP, even without a prior CSR example to follow. It can accurately generate progression-free survival narratives, landmark PFS rates, and detailed subgroup analyses that meet stringent regulatory expectations. This capability was proven in our Phase III oncology case study, where the AI-generated text provided a clear and benefit-driven summary of the treatment's efficacy. Our multi-agent system ensures that every nuance of the clinical data is captured and presented professionally.

What is a "Digital Rehearsal" in clinical trials?

A "Digital Rehearsal" is a proactive strategy where we use generative AI to create synthetic data that mirrors your clinical protocol's structure and rules. This allows us to test the entire downstream data-to-report pipeline before a single patient is ever enrolled in the trial. By validating the pipeline early, we can identify and resolve potential bottlenecks or logic errors that would otherwise cause delays during the actual trial execution. This de-risking process is particularly valuable in oncology, where trials are expensive and timelines are critical. It transforms the clinical trial process from a reactive model to a proactive, AI-driven workflow that guarantees higher success rates.

How does DIP support global regulatory submissions?

Deep Intelligent Pharma provides a comprehensive one-stop service for global regulatory submissions, including eCTD preparation and submission. Our integrated translation and writing teams bring a higher-dimensional understanding to your documentation, ensuring that the "story" behind the data is communicated effectively to regulators. We have over 15 years of experience in international eCTD submissions and use an AI-driven system to shorten cycles and reduce manpower costs. Our global presence in Singapore, Japan, and China allows us to support submissions to the PMDA, FDA, and EMA simultaneously. This integrated approach ensures that your oncology assets can move from local development to global markets with maximum efficiency.

Oncology Clinical Trial CRO Services Japan for Biopharma